About Hi-Tech Pharmacal (NASDAQ:HITK)
Hi-Tech Pharmacal Co., Inc. is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products. The Company develops, manufactures and markets products in three categories: generics, prescription brands and over-the-counter (OTC) brands. It produces a range of products for various disease states, including glaucoma, asthma, bronchial disorders, dermatological disorders, allergies, pain, stomach, oral care and other conditions. The Company's generic products are primarily prescription items and include oral solutions and suspensions, topical creams and ointments as well as nasal sprays. It also specializes in the manufacture of products in its sterile facility capable of producing liquid ophthalmic, otic and inhalation products. In April 2014, Akorn Inc acquired Hi-Tech Pharmacal Co., Inc.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Hi-Tech Pharmacal (NASDAQ:HITK) Frequently Asked Questions
What is Hi-Tech Pharmacal's stock symbol?
Hi-Tech Pharmacal trades on the NASDAQ under the ticker symbol "HITK."
Who are some of Hi-Tech Pharmacal's key competitors?
Some companies that are related to Hi-Tech Pharmacal include GlaxoSmithKline (GSK), AstraZeneca (AZN), Beximco Pharmaceuticals (BXP), Shire (SHP), Hikma Pharmaceuticals (HIK), BTG (BTG), CoLucid Pharmaceuticals (CLCD), SciClone Pharmaceuticals (SCLN), SkyePharma (SKP), Diurnal Group (DNL), Allergy Therapeutics (AGY), Innocoll (INNL), Aegerion Pharmaceuticals (AEGR), Amryt Pharma (AMYT), N4 Pharma (N4P), Venture Life Group (VLG), SLS International (SLS) and Avanir Pharmaceuticals (AVNR).
Has Hi-Tech Pharmacal been receiving favorable news coverage?
News articles about HITK stock have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hi-Tech Pharmacal earned a media sentiment score of 0.22 on Accern's scale. They also assigned news coverage about the healthcare company an impact score of 45.08 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Hi-Tech Pharmacal?
Shares of HITK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Hi-Tech Pharmacal?
Hi-Tech Pharmacal's mailing address is 369 Bayview Ave, AMITYVILLE, NY 11701-2801, United States. The healthcare company can be reached via phone at +1-516-7898228.
MarketBeat Community Rating for Hi-Tech Pharmacal (HITK)MarketBeat's community ratings are surveys of what our community members think about Hi-Tech Pharmacal and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Hi-Tech Pharmacal (NASDAQ:HITK) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Hi-Tech Pharmacal (NASDAQ:HITK) Earnings History and Estimates Chart
Hi-Tech Pharmacal (NASDAQ HITK) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/11/2014||Q314||$0.66||$0.70||$62.35 million||$59.90 million||View||N/A|
|12/10/2013||Q2||$0.47||$0.71||$57.97 million||$58.60 million||View||N/A|
|9/9/2013||Q1 2014||$0.44||$0.44||$57.78 million||$50.50 million||View||Listen|
|7/9/2013||Q4 2013||$0.63||$0.50||$66.33 million||$58.50 million||View||Listen|
|3/7/2013||Q3 2013||$0.71||$0.43||$60.45 million||$64.33 million||View||Listen|
|9/5/2012||Q113||$0.68||$0.44||$57.60 million||$52.00 million||View||N/A|
|12/9/2010||$0.56||$0.76||$42.47 million||$44.90 million||View||N/A|
Hi-Tech Pharmacal (NASDAQ:HITK) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Hi-Tech Pharmacal (NASDAQ:HITK)
No dividend announcements for this company have been tracked by MarketBeat.com
Hi-Tech Pharmacal (NASDAQ HITK) Insider Trading and Institutional Ownership History
Hi-Tech Pharmacal (NASDAQ HITK) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/13/2013||Gary April||Insider||Sell||6,873||$43.06||$295,951.38|| |
|10/10/2013||Reuben Seltzer||Chairman||Sell||11,250||$43.13||$485,212.50||521,510|| |
|10/8/2013||David Seltzer||CEO||Sell||23,000||$43.09||$991,070.00||1,339,612|| |
|10/4/2013||Martin Goldwyn||Director||Sell||1,500||$43.10||$64,650.00|| |
|10/3/2013||William J Peters||CFO||Sell||21,250||$43.11||$916,087.50|| |
|10/2/2013||Bruce W Simpson||Director||Sell||25,468||$43.15||$1,098,944.20|| |
|10/2/2013||Reuben Seltzer||Chairman||Sell||11,250||$43.13||$485,212.50|| |
|2/5/2013||William J Peters||CFO||Sell||4,639||$38.00||$176,282.00|| |
Hi-Tech Pharmacal (NASDAQ HITK) News Headlines
Hi-Tech Pharmacal (NASDAQ:HITK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Hi-Tech Pharmacal (NASDAQ:HITK) Income Statement, Balance Sheet and Cash Flow Statement
Hi-Tech Pharmacal (NASDAQ HITK) Stock Chart for Tuesday, March, 20, 2018